Ready-to-use AAV8 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

An adeno-associated viral vector expressing nuclear envelope-embedded eGFP and a Cre-dependent guide RNA for mGrid1

Ready-to-use AAV Retrograde particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

An AAV packaging vector that expresses ER-retained low-affinity GCaMP3 variant under control of the EF1a promoter.

An AAV packaging vector that expresses ER-retained low-affinity GCaMP3 variant under control of the SYN1 promoter.

CRISPR‐Cas9 tool for the genetic engineering of Bacillus phages

Expression of Smoothened

Elastin Like Polypeptide: [(VPGEG)-(VPGVG)4-(VPGAG)2-(VPGGG)2-(VPGEG)]2, with N-Terminal Cysteine and C-Terminal Sortase Recognition Sequence LPETGG

Elastin Like Polypeptide: [(VPGEG)-(VPGVG)4-(VPGAG)2-(VPGGG)2-(VPGEG)]2, with N-Terminal Sortase Recognition Sequence GGG and a C-terminal Cysteine

Elastin Like Polypeptide: [(VPGEG)-(VPGVG)4-(VPGAG)2-(VPGGG)2-(VPGEG)]6, with N-Terminal Sortase Recognition Sequence GGG and a C-terminal Cysteine

Elastin Like Polypeptide: [(VPGEG)-(VPGVG)4-(VPGAG)2-(VPGGG)2-(VPGEG)]6, with N-Terminal Cysteine and C-Terminal Sortase Recognition Sequence LPETGG

CBM-Xmod-DocIII handle with N-Terminal Sortase Recognition Sequence GGG for posttranslational coupling to a C-Terminal LPETGG

CohIII-CBM handle with C-Terminal Sortase Recognition Sequence LPETGG for Posttranslational Coupling to a N-terminal GGG

pCR®2.1-TOPO® backbone with 3' end of HIV-1(HXB2:9045 till poly-A (20))

Bacterial Strain with Genotype: MC4100 ∆clpPX